Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D09OOQ
|
||||
| Former ID |
DIB013286
|
||||
| Drug Name |
TGFK08AA-ER
|
||||
| Indication | Generalized anxiety disorder [ICD9: 300, 300.02, 311; ICD10:F32, F40-F42, F41.1] | Phase 2 | [1] | ||
| Company |
Fabre Kramer Pharmaceuticals Inc
|
||||
| Target and Pathway | |||||
| Target(s) | 5-hydroxytryptamine 1A receptor | Target Info | Modulator | [2] | |
| KEGG Pathway | cAMP signaling pathway | ||||
| Neuroactive ligand-receptor interaction | |||||
| Serotonergic synapse | |||||
| PANTHER Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | ||||
| 5HT1 type receptor mediated signaling pathway | |||||
| Reactome | Serotonin receptors | ||||
| G alpha (i) signalling events | |||||
| WikiPathways | Serotonin HTR1 Group and FOS Pathway | ||||
| SIDS Susceptibility Pathways | |||||
| Monoamine GPCRs | |||||
| GPCRs, Class A Rhodopsin-like | |||||
| GPCR ligand binding | |||||
| GPCR downstream signaling | |||||
| References | |||||
| REF 1 | Clinical pipeline report, company report or official report of Fabre-Kramer Pharmaceuticals. | ||||
| REF 2 | 50 years of hurdles and hope in anxiolytic drug discovery. Nat Rev Drug Discov. 2013 Sep;12(9):667-87. doi: 10.1038/nrd4075. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.